These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6740209)

  • 1. Screening for occult faecal blood loss in a community by means of Hemoccult II slides and a tetramethylbenzidine test.
    Dybdahl JH; Haug K; Bakkevold K; Olsen KO; Vetvik K
    Scand J Gastroenterol; 1984 May; 19(3):343-9. PubMed ID: 6740209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occult faecal blood loss determined by a 51Cr method and chemical tests in patients referred for colonoscopy.
    Dybdahl JH; Daae LN; Larsen S; Myren J
    Scand J Gastroenterol; 1984 Mar; 19(2):245-54. PubMed ID: 6609422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of the study of occult fecal blood with Hemoccult II in 211 symptomatic patients controlled by total colonoscopy].
    Morini S; Manurita L; Stroppa I; Bassi O
    Minerva Med; 1984 Apr; 75(17):963-6. PubMed ID: 6728249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occult faecal blood loss determined by a 51Cr method and chemical tests in patients referred for upper gastrointestinal endoscopy.
    Dybdahl JH
    Scand J Gastroenterol; 1984 Mar; 19(2):235-44. PubMed ID: 6609421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occult-blood screening for colorectal carcinoma: the risks.
    Frank JW
    Am J Prev Med; 1985; 1(4):25-32. PubMed ID: 3870908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for gastrointestinal neoplasia: efficacy and cost of two different approaches in a clinical rehabilitation centre.
    Manus B; Brägelmann R; Armbrecht U; Stolte M; Stockbrügger RW
    Eur J Cancer Prev; 1996 Feb; 5(1):49-55. PubMed ID: 8664809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal occult blood testing: clinical value and limitations.
    Simon JB
    Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occult-blood screening for colorectal carcinoma: the yield and the costs.
    Frank JW
    Am J Prev Med; 1985; 1(5):18-24. PubMed ID: 3939711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Randomized population study of screening for intestinal cancer with Hemoccult-II].
    Kronborg O; Fenger C; Olsen J; Jørgensen OD; Søndergaard O
    Ugeskr Laeger; 1997 Aug; 159(33):4977-81. PubMed ID: 9281212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemoccult test as a routine screening procedure for colorectal disease in the private clinic setting.
    Stewart HL; Wiens E
    Can J Surg; 1979 Nov; 22(6):572-4. PubMed ID: 497930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of colorectal carcinoma. Annual hemoccult test and sigmoidoscopy every 5 years].
    Rosenbaum A; Riemann JF
    MMW Fortschr Med; 2000 Aug; 142(31-32):27-9. PubMed ID: 10992763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic significance of immunohistochemical fecal occult blood test in subjects receiving bidirectional endoscopy.
    Liu HH; Huang TW; Chen HL; Wang TH; Lin JT
    Hepatogastroenterology; 2003; 50(53):1390-2. PubMed ID: 14571744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endoscopic findings in the upper gastrointestinal tract of faecal occult blood-positive, colonoscopy-negative patients.
    Hisamuddin K; Mowat NA; Phull PS
    Dig Liver Dis; 2006 Jul; 38(7):503-7. PubMed ID: 16522381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas.
    Macrae FA; St John DJ
    Gastroenterology; 1982 May; 82(5 Pt 1):891-8. PubMed ID: 7060910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Screening for colorectal cancer with an immunological fecal occult blood test].
    Fernández JL; Gallegos M; Brochero A; Arévalo C; Piccioni H; Gutiérrez Galiana H
    Acta Gastroenterol Latinoam; 1999; 29(2):73-8. PubMed ID: 10491719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test.
    Levi Z; Hazazi R; Rozen P; Vilkin A; Waked A; Niv Y
    Aliment Pharmacol Ther; 2006 May; 23(9):1359-64. PubMed ID: 16629942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.
    Lindholm E; Brevinge H; Haglind E
    Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
    Musil D; Tillich J
    Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occult faecal blood loss determined by chemical tests and a 51 Cr method.
    Dybdahl JH; Daae LN; Larsen S
    Scand J Gastroenterol; 1981; 16(2):245-52. PubMed ID: 7313535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.